Skip to content

CeriBell, Inc. CBLL Investment Proceeds

Investment Proceeds at other companies

Edwards Lifesciences logo
Edwards LifesciencesEW

Other financials

Income statement

See full
Revenue$26.5M+29.3%
Gross profit$23.1M+28.4%
Operating income-$20.7M-46.0%
Net income-$19.7M-54.5%
EPS (diluted)-$0.52-44.4%

Balance sheet

See full
Cash & equivalents$45.3M-70.5%
Total debt$22.1M+1.6%
Total equity$140.8M-22.2%
Total assets$178.1M-16.6%

Cash flow

See full
Operating cash flow-$19.3M-69.2%
CapEx$125.0K-15.5%
Free cash flow-$19.4M-68.1%

Valuation

See full
Market cap$748.61M+15.6%
Enterprise value$725.47M+40.7%
P/S7.9×-1.2×

Profitability

See full
Gross margin87.7%+0.5pp
Operating margin-68.3%+5.5pp
Net margin-63.5%+1.0pp
FCF margin-52%-1.4pp

Returns & leverage

See full
Return on equity-37.5%
Debt / equity0.2×0.0×
Current ratio10.4×-6.9×

Where this comes from

Reported directly by CeriBell, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: CeriBell, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about CeriBell, Inc.'s investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CeriBell, Inc.'s investment proceeds?
CeriBell, Inc. (CBLL) reported investment proceeds of $50M in Q1 2026.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.